Akshanth R Polepally

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 10

Top Topics

Atopic Dermatitis

Neuropathic Pain

Multiple Myeloma

Top Venues

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Carla Biesdorf, Xiaowen Guan, Satya R Siddani, David Hoffman, Nils Boehm, Bruno C Medeiros, Toshihiko Doi, Maja de Jonge, Drew Rasco, Rajeev M Menon, Akshanth R Polepally
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study. Cancer chemotherapy and pharmacology (2023)
Anita D Souza, Nina Shah, Cesar Rodriguez, Peter M Voorhees, Katja Weisel, Orlando F Bueno, Rajvineeth K Pothacamury, Kevin J Freise, Susan Yue, Jeremy A Ross, Akshanth R Polepally, Chetasi Talati, Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji K Kumar
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (31) (2022)
Mohamad Shebley, Akshanth R Polepally, Ahmed Nader, Juki W Ng, Insa Winzenborg, Cheri E Klein, Peter Noertersheuser, Megan A Gibbs, Nael M Mostafa
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical pharmacokinetics 59 (3) (2021)
George D Demetri, Jason John Luke, Antoine Hollebecque, John D Powderly, Alexander I Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W Lai, Huibin Yue, Akshanth R Polepally, James W Purcell, Randy R Robinson, Padmanee Sharma, James P Allison, Anthony Tolcher, Victor M Villalobos
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (13) (2021)
Akshanth R Polepally, Juki W Ng, Ahmed Hamed Salem, Matthew B Dufek, Apurvasena Parikh, David C Carter, Kent Kamradt, Nael M Mostafa, Mohamad Shebley
Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of clinical pharmacology 60 (12) (2020)
Insa Winzenborg, Akshanth R Polepally, Ahmed Nader, Nael M Mostafa, Peter Noertersheuser, Juki W Ng
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model. CPT: pharmacometrics & systems pharmacology 9 (8) (2020)
Insa Winzenborg, Ahmed Nader, Akshanth R Polepally, Mohan Liu, Jacob Degner, Cheri E Klein, Nael M Mostafa, Peter Noertersheuser, Juki Ng
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical pharmacokinetics 57 (10) (2019)
Amit Khatri, Ahmed A Suleiman, Akshanth R Polepally, Ahmed A Othman
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients. Clinical pharmacology and therapeutics 107 (2) (2019)
Sathej M Gopalakrishnan, Akshanth R Polepally, Sven Mensing, Amit Khatri, Rajeev M Menon
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical pharmacokinetics 56 (1) (2017)
Akshanth R Polepally, Sven Mensing, Amit Khatri, Denise Beck, Wei Liu, Walid M Awni, Rajeev M Menon, Sandeep Dutta
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical pharmacokinetics 55 (9) (2017)